Lutz W K
J Cancer Res Clin Oncol. 1986;112(2):85-91. doi: 10.1007/BF00404387.
Investigation of covalent DNA binding in vivo provided evidence for whether a test substance can be activated to metabolites able to reach and react with DNA in an intact organism. For a comparison of DNA binding potencies of various compounds tested under different conditions, a normalization of the DNA lesion with respect to the dose is useful. A covalent binding index, CBI = (mumol chemical bound per mol DNA nucleotide)/(mmol chemical administered per kg body weight) can be determined for each compound. Whether covalent DNA binding results in tumor formation is dependent upon additional factors specific to the cell type. Thus far, all compounds which bind covalently to liver DNA in vivo have also proven to be carcinogenic in a long-term study, although the liver was not necessarily the target organ for tumor growth. With appropriate techniques, DNA binding can be determined in a dose range which may be many orders of magnitude below the dose levels required for significant tumor induction in a long-term bioassay. Rat liver DNA binding was proportional to the dose of aflatoxin B1 after oral administration of a dose between 100 micrograms/kg and 1 ng/kg. The lowest dose was in the range of general human daily exposures. Demonstration of a lack of liver DNA binding (CBI less than 0.1) in vivo for a carcinogenic, nonmutagenic compound is a strong indication for an indirect mechanism of carcinogenic action. Carcinogens of this class do not directly produce a change in gene structure or function but disturb a critical biochemical control mechanism, such as protection from oxygen radicals, control of cell division, etc. Ultimately, genetic changes are produced indirectly or accumulate from endogenous genotoxic agents. The question of why compounds which act via indirect mechanisms are more likely to exhibit a nonlinear range in the dose-response curve as opposed to the directly genotoxic agents or processes is discussed.
对体内共价DNA结合的研究为测试物质是否能被激活成能够在完整生物体中与DNA接触并发生反应的代谢产物提供了证据。为了比较在不同条件下测试的各种化合物的DNA结合能力,对DNA损伤进行剂量归一化是有用的。可以为每种化合物确定一个共价结合指数,CBI =(每摩尔DNA核苷酸结合的化学物质微摩尔数)/(每千克体重施用的化学物质毫摩尔数)。共价DNA结合是否导致肿瘤形成取决于特定细胞类型的其他因素。到目前为止,所有在体内与肝脏DNA共价结合的化合物在长期研究中也已被证明具有致癌性,尽管肝脏不一定是肿瘤生长的靶器官。通过适当的技术,可以在一个剂量范围内确定DNA结合,该剂量范围可能比长期生物测定中显著诱导肿瘤所需的剂量水平低许多个数量级。口服剂量在100微克/千克至1纳克/千克之间时,大鼠肝脏DNA结合与黄曲霉毒素B1的剂量成正比。最低剂量处于一般人类每日暴露范围内。对于一种致癌但非诱变的化合物,体内肝脏DNA结合缺乏(CBI小于0.1)的证明强烈表明其致癌作用的间接机制。这类致癌物不会直接引起基因结构或功能的改变,而是干扰关键的生化控制机制,如对氧自由基的保护、细胞分裂的控制等。最终,遗传变化是间接产生的或由内源性基因毒性剂积累而成。讨论了为什么通过间接机制起作用的化合物与直接基因毒性剂或过程相比更有可能在剂量反应曲线中表现出非线性范围的问题。